Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 18/20 | 0.69 |
| ▸ | ADRB2 | P07550 | 16/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 16/20 | 0.69 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7716895 | 0.91 | ADRB3 (0.57) | ADRB3ADRB2ADRB1ADRA1DADRA1A | |
| SCHEMBL7716930 | 0.88 | ADRB3 (0.73) | ADRB3ADRB2ADRB1ADRA1DADRA1A | |
| SCHEMBL7714620 | 0.87 | ADRB3 (0.74) | ADRB3ADRB2ADRB1ADRA1DADRA1A | |
| SCHEMBL9268240 | 0.82 | ADRB2 (1.00) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7714838 | 0.81 | ADRB3 (0.69) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7714629 | 0.81 | ADRB3 (0.69) | ADRB3ADRB2ADRB1 | |
| SCHEMBL9268335 | 0.81 | ADRB3 (1.00) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7712901 | 0.80 | ADRB3 (0.64) | ADRB3ADRB2ADRB1ADRA1DADRA1A | |
| SCHEMBL9267558 | 0.78 | ADRB3 (0.73) | ADRB3ADRB2ADRB1ADRA1DADRA1A | |
| SCHEMBL7717196 | 0.77 | ADRB3 (0.63) | ADRB3ADRB2ADRB1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0865421-B1 | ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS AGONISTS OF ATYPICAL BETA-ADRENOCEPTORS | GLAXO GROUP LTD (GB) | 2002-03-27 | — | — | EP | claimed |
| EP-0865421-A1 | ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS AGONISTS OF ATYPICAL BETA-ADRENOCEPTORS | GLAXO GROUP LIMITED (GB) | 1998-09-23 | — | — | EP | claimed |
| WO-1997021665-A1 | ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS AGONISTS OF ATYPICAL BETA-ADRENOCEPTORS | GLAXO GROUP LIMITED (GB) | 1997-06-19 | — | — | WO | claimed |
| EP-0865421-B1 | ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS AGONISTS OF ATYPICAL BETA-ADRENOCEPTORS | GLAXO GROUP LTD (GB) | 2002-03-27 | — | — | EP | disclosed |
| US-6048872-A | DIETETICS; ANTIDIABETIC AGENTS; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS | GLAXO WELLCOME INC. (US) | 2000-04-11 | — | — | US | disclosed |
| EP-0865421-A1 | ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS AGONISTS OF ATYPICAL BETA-ADRENOCEPTORS | GLAXO GROUP LIMITED (GB) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997021665-A1 | ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS AGONISTS OF ATYPICAL BETA-ADRENOCEPTORS | GLAXO GROUP LIMITED (GB) | 1997-06-19 | — | — | WO | disclosed |